Pharma BD Deal Intelligence
A validation win dressed as a bargain: Affimed took just $96M upfront against $5.0B in Genentech milestones, and the market agreed, sending shares up 158% to $4.12—though the deal is almost entirely backloaded biobucks.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Affimed shares more than doubled to $4.12, up 158% from the prior close of $1.60, on the Genentech deal — a clear positive market reaction.
FierceBiotech noted the deal was heavily backloaded — only $96M upfront against $5B in milestones — but praised the Genentech validation as transformational…
Coverage emphasized the Genentech deal as a strategic fit that boosts Affimed's cash runway and validates the ROCK platform as a credible bispecific modality.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Affimed and Genentech (Roche) entered an August 2018 strategic collaboration to develop NK cell engager-based immunotherapeutics. Affimed received $96M upfront and near-term funding plus up to $5.0B in development, regulatory, and commercial milestones across multiple undisclosed solid and hematologic tumor targets. Affimed leads early research using its ROCK platform; Genentech leads clinical development and commercialization worldwide.
$74.0B Global immuno-oncology market 2024 (forecast)
Innate immune cell engagers — particularly NK cell engagers — are a rising class of cancer immunotherapies designed to redirect natural killer and T cells against tumor antigens through tetravalent or multispecific antibody constructs. The class promises broader applicability and lower cytokine-release toxicity versus first-generation T-cell engagers (BiTEs), with potential across both solid and hematologic tumors.
The bispecific antibody and innate immune cell engager landscape in 2018 was crowded with platform plays. Amgen's Blincyto (blinatumomab), an anti-CD19/CD3 BiTE, was the only approved T-cell engager at the time and validated the modality in B-ALL. Roche/Genentech itself was investing heavily in CD20-bispecifics (mosunetuzumab, glofitamab) for B-cell lymphomas. Other bispecific platform plays competing for big-pharma capital included MacroGenics' DART, Xencor's bispecific Fc, and Innate Pharma's NK-targeting antibodies. Affimed's ROCK platform differentiated on tetravalent format and CD16A engagement of NK cells, positioning it as a complement rather than substitute to checkpoint inhibitors. The Genentech deal — $96M upfront and up to $5.0B in milestones — was widely viewed as third-party validation of the NK-engager thesis, with Endpoints News describing it as a 'Cinderella story' for the small German biotech and shares more than doubling on announcement. The collaboration was effectively wound down by mid-2025 after Affimed restructured, though Genentech advanced a selected target into IND-enabling studies.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Genentech, Inc. (Roche Group) / Affimed N.V. (this deal) | 2018 | $5.1B | — |
| Genentech, Inc. (Roche Group) / Duality Biologics (Suzhou) Co. Ltd. | 2026 | $1.0B | 100 |
| Genentech, Inc. (Roche Group) / Hanmi Pharmaceutical Co. Ltd. | 2026 | $2.3B | 100 |
| Genentech, Inc. (Roche Group) / Tanox Inc. | 2006 | $919M | 80 |
| Genentech, Inc. (Roche Group) / Astex Pharmaceuticals | 2026 | $490M | 58 |
| Genentech, Inc. (Roche Group) / Hanmi Pharmaceutical Co. Ltd. | 2016 | $910M | — |
| Genentech, Inc. (Roche Group) / Regor Pharmaceuticals Inc. | 2024 | $850M | — |
← Browse all deals · How we score deals
More: 2018 deals · Genentech, Inc. (Roche Group) deals · Hematology deals